+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Mexico Insulin Drugs And Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

  • PDF Icon


  • 70 Pages
  • February 2024
  • Region: Mexico
  • Mordor Intelligence
  • ID: 5854468
The Mexico Insulin Drugs And Delivery Devices Market size is estimated at USD 546.96 million in 2024, and is expected to reach USD 572.01 million by 2029, growing at a CAGR of 0.9% during the forecast period (2024-2029).

Diabetes is a chronic condition demanding self-management and care, which involves regular attention to food, physical activity, blood sugar monitoring, and the use of medications. People with chronic diseases such as diabetes mellitus and obesity have a worse prognosis of COVID-19. Diabetic people are twice as likely to have their comorbid conditions worsened and consequently die. The healthcare system must be better organized for more severe cases of COVID-19 as studies suggest that inadequate glycemic control increases the risk of undesired outcomes in diabetic patients with SARS-CoV-2 infection. The prevalence of diabetes in people hospitalized with COVID-19 infection and the recognition that improved glycemic control might improve outcomes and reduce the length of stay in patients with COVID-19 have underlined the importance of diabetes care.

Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications from COVID-19. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.

In Mexico, diabetes, especially Type 2, became a healthcare burden as it is the primary cause of death among women and the secondary cause of death among men. Obesity, sedentarism, bad eating habits, genetics, family background, and age are among the factors that lead to developing diabetes. The pandemic also highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care, through virtual consultations between healthcare providers and people with diabetes, and the use of diabetes technology. Thus, the COVID-19 outbreak increased the insulin market's growth.

Mexico Insulin Drugs And Delivery Devices Market Trends

Rising diabetes prevalence

In Mexico, the diabetes population is expected to rise by about 3.4% over the forecast period.

According to IDF Diabetes Atlas 2021, the prevalence of diabetes in Mexico reached 16.9%, or one in six adults. An estimated 14 million adults in Mexico are living with diabetes. Additionally, 11 million adults in the country have impaired glucose tolerance, which places them at high risk of developing type 2 diabetes. Diabetes-related health expenditure in Mexico has reached USD 20 billion, putting it in the top ten countries or territories with the highest total health expenditure. About 47.5% of people living with diabetes in the country are undiagnosed.

Lack of health insurance deprives the poor of access to services and puts them at risk of financial hardship. To protect the people against excessive health expenditures, Mexico has implemented mechanisms such as community-based health insurance, national health insurance, and targeted public health insurance. Mexico has multiple health insurance providers. The Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (State Employee's Social Security and Social Services Institute, ISSSTE) provides coverage for government employees, and the Instituto Mexicano del Seguro Social (Mexican Social Security Institute, IMSS) covers for private-sector employees. The Seguro Popular (People's Insurance) was launched to protect the working-age population against steep healthcare costs. Enrolment in the Seguro Popular is independent of health status or pre-existing illness; there is no co-payment by the type of health care received, and family contributions are determined solely by the ability to pay.

Leading manufacturers focus on technological innovations and develop advanced insulin products to gain a substantial market share. There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels.

Therefore, owing to the increasing diabetes prevalence, the studied market is anticipated to grow over the analysis period.

The insulin pumps segment is expected to witness the highest growth rate over the forecast period

An insulin pump is a device that delivers insulin continuously or, whenever required, automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen.

Insulin Pump is expected to grow with a CAGR of about 9.9% in the market during the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration. Insulin pump therapy is a well-established insulin administration method for type 1 diabetes people. Pumps are a validated, time-tested therapeutic option in type 1 diabetes at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.

The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients must check their blood glucose levels regularly, monitor their blood glucose levels, and adjust the insulin dosing accordingly, likely to drive segment growth during the forecast period. The use of continuous subcutaneous insulin infusion and continuous glucose monitoring systems has improved patient care and quality of life and is widely used in the ambulatory setting. Increasingly, this technology is also being used in the hospital setting.

The factors above are anticipated to drive market growth over the analysis period.

Mexico Insulin Drugs And Delivery Devices Industry Overview

The Mexico Insulin Drugs and Delivery Devices Market is moderately consolidated, with few significant and generic players. Mergers and acquisitions between the players recently have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5.1 Drug
5.1.1 Basal or Long-acting Insulins Lantus (Insulin Glargine) Levemir (Insulin Detemir) Toujeo (Insulin Glargine) Tresiba (Insulin Degludec) Basaglar (Insulin Glargine)
5.1.2 Bolus or Fast-acting Insulins NovoRapid/Novolog (Insulin aspart) Humalog (Insulin lispro) Apidra (Insulin glulisine) FIASP (Insulin aspart) Admelog (Insulin lispro Sanofi)
5.1.3 Traditional Human Insulins Novolin/Mixtard/Actrapid/Insulatard Humulin Insuman
5.1.4 Combination Insulins NovoMix (Biphasic Insulin aspart) Ryzodeg (Insulin degludec and Insulin aspart) Xultophy (Insulin degludec and Liraglutide) Soliqua/Suliqua (Insulin glargine and Lixisenatide)
5.1.5 Biosimilar Insulins Insulin Glargine Biosimilars Human Insulin Biosimilars
5.2 Device
5.2.1 Insulin Pumps Insulin Pump Devices Insulin Pump Reservoirs Insulin Infusion sets
5.2.2 Insulin Pens Cartridges in reusable pens Disposable insulin pens
5.2.3 Insulin Syringes
5.2.4 Insulin Jet Injectors
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 Biocon
7.1.5 Julphar
7.1.6 Medtronic
7.1.7 Ypsomed
7.1.8 Becton Dickinson
7.2.1 Insulin Drugs Novo Nordisk Sanofi Eli Lilly
7.2.2 Insulin Delivery Devices Medtronic Ypsomed Becton Dickinson

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • Biocon
  • Julphar
  • Medtronic
  • Ypsomed
  • Becton Dickinson